Abstract
Experiments were designed to test what percentage of experimental MC-induced murine sarcomas were sensitive to the local tumour inhibitory effect of IL-2 and whether any correlation existed between the sensitivity of these sarcomas to the immunotherapeutic effect of IL-2 and their susceptibility to the cytolytic effect of IL-2-activated killer cells. It was found that the sensitivity of MC-induced sarcomas to local IL-2 immunotherapy was a general phenomenon. Repeated peri-tumoural injections of RIL-2 inhibited the growth of five (MC11, MC13, MC14, MC15, MC16) out of six sarcomas in syngeneic mice. The sixth murine sarcoma (MC12) was found to be resistant to the tumour inhibitory effect of IL-2. Similarly, five (MC11, MC13, MC14, MC15, MC16) out of six murine sarcoma cell lines were sensitive to the cytolytic effect of IL-2-activated syngeneic killer spleen cells when examined in vitro, whereas the sixth (MC12) sarcoma cell line was resistant. These results suggest that LAK cells represent the effector cell mechanism responsible for the anti-tumour efficacy of local IL-2 immunotherapy and that in vitro testing of sensitivity to the LAK cell-mediated cytolysis may be used to detect tumours responding to IL-2 immunotherapy in vivo.
Keywords: Sarcoma, Killer Cell, Effector Cell, Spleen Cell, General Phenomenon
Abbreviations
- IL-2
interleukin 2
- RIL-2
human recombinant interleukin 2
- LAK
lymphokine-activated killer
- MC
3-methylcholanthrene
- B10
C57BL/10ScSnPh
- MSV
murine sarcoma virus (Harvey)
- MEM
minimal essential medium
References
- 1.Bubeník J, Turano A, Fadda G. Prevention of carcinogenesis by murine sarcoma virus (Harvey) following injections of immune sera during the latent period. Int J Cancer. 1969;4:648. doi: 10.1002/ijc.2910040510. [DOI] [PubMed] [Google Scholar]
- 2.Bubeník J, Indrová M, Němečková Š, Malkovský M, von Broen B, Pálek V, Anderlíková J. Solubilized tumour-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests. Int J Cancer. 1978;21:348. doi: 10.1002/ijc.2910210316. [DOI] [PubMed] [Google Scholar]
- 3.Bubeník J, Jandlová T, Šuhajová E, Malkovský M. Cell surface adhesiveness of mouse sarcoma lines evaluated by Latex particle adherence assay: Correlation with growth behavior and electrophoretic mobility. Neoplasma. 1979;26:499. [PubMed] [Google Scholar]
- 4.Bubeník J, Perlmann P, Indrová M, Šímová J, Jandlová T, Neuwirt J. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol Immunother. 1983;14:205. doi: 10.1007/BF00205362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bubeník J, Indrová M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcová A. Tumour inhibitory effect of TCGF (IL-2)-containing preparations. Cancer Immunol Immunother. 1985;19:57. doi: 10.1007/BF00199313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bubeník J, Kieler J, Indrová M. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice. Folia Biol. 1986;32:209. [PubMed] [Google Scholar]
- 7.Bubeník J, Kieler J, Tromholt V, Steven K, Indrová M, Toulcová A. Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2. Folia Biol. 1986;32:183. [PubMed] [Google Scholar]
- 8.Cheever MA, Thompson JA, Kern DE, Greenberg PD. Interleukin 2 (IL 2) administered in vivo: Influence of IL 2 route and timing on T cell growth. J Immunol. 1985;134:3895. [PubMed] [Google Scholar]
- 9.Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol. 1983;130:2203. [PubMed] [Google Scholar]
- 10.Donohue JH, Lotze MT, Robb RJ, Rosenstein M, Braziel RM, Jaffe ES, Rosenberg SA. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res. 1984;44:1380. [PubMed] [Google Scholar]
- 11.Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol. 1985;135:3623. [PubMed] [Google Scholar]
- 12.Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985;45:3735. [PubMed] [Google Scholar]
- 13.Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985;134:157. [PubMed] [Google Scholar]
- 14.Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer M-C, Rosenberg SA. In vivo administration of purified human interleukin 2. II. Half-life, immunologic effect, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985;135:2865. [PubMed] [Google Scholar]
- 15.Mühlradt PF, Opitz HG. Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. Eur J Immunol. 1982;12:983. doi: 10.1002/eji.1830121117. [DOI] [PubMed] [Google Scholar]
- 16.Mulé JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985;135:646. [PubMed] [Google Scholar]
- 17.Pizza G, Severini G, Menniti D, De Vinci C, Corrado F. Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Int J Cancer. 1984;34:359. doi: 10.1002/ijc.2910340312. [DOI] [PubMed] [Google Scholar]
- 18.Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161:1169. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]